Thanarath Imsuwansri

Dr. Thanarath Imsuwansri

orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2012 in Clinical and Experimental Otorhinolaryngology
Verified
Journal Article
Open access
PDF file
TIThanarath Imsuwansri
Thanarath Imsuwansri
PPPipat Poonsap
Pipat Poonsap
KSKornkiat Snidvongs
Kornkiat Snidvongs
Systemic and intratympanic steroids are most widely used for treating idiopathic sudden sensorineural hearing loss. Other treatments include vasodilator, immunosuppressant and antiviral medication. However, only 61% of patients achieve full recovery, and controversies about the standard treatment still exist. In this case report, we present a patient with idiopathic sudden sensorineural hearing loss who failed to respond to systemic and intratympanic steroid treatments but subsequently recovered after undergoing hyperbaric oxygen therapy.

20 September 2023 in Scientific Reports
Verified
Journal Article
Open access
PDF file
TIThanarath Imsuwansri
Thanarath Imsuwansri
TJThitinan Jongthitinon
Thitinan Jongthitinon
NPNiramon Pojdoung
Niramon Pojdoung
NMNuntana Meesiripan
Nuntana Meesiripan
SSSiriwan Sakarin
Siriwan Sakarin
TPTrairak Pisitkun
Trairak Pisitkun
An HPMC-based nasal spray solution containing human IgG1 antibodies against SARS-CoV-2 (nasal antibody spray or NAS) was developed to strengthen COVID-19 management. NAS exhibited potent broadly neutralizing activities against SARS-CoV-2 with PVNT50 values ranging from 0.0035 to 3.1997 μg/ml for the following variants of concern (ranked from lowest to highest): Alpha, Beta, Gamma, ancestral, Delta, Omicron BA.1, BA.2, BA.4/5, and BA.2.75. Biocompatibility assessment showed no potential biological risks. Intranasal NAS administration in rats showed no circulatory presence of human IgG1 anti-SARS-CoV-2 antibodies within 120 h. A double-blind, randomized, placebo-controlled trial (NCT05358873) was conducted on 36 healthy volunteers who received either NAS or a normal saline nasal spray. Safety of the thrice-daily intranasal administration for 7 days was assessed using nasal sinuscopy, adverse event recording, and self-reporting questionnaires. NAS was well tolerated, with no significant adverse effects during the 14 days of the study. The SARS-CoV-2 neutralizing antibodies were detected based on the signal inhibition percent (SIP) in nasal fluids pre- and post-administration using a SARS-CoV-2 surrogate virus neutralization test. SIP values in nasal fluids collected immediately or 6 h after NAS application were significantly increased from baseline for all three variants tested, including ancestral, Delta, and Omicron BA.2. In conclusion, NAS was safe for intranasal use in humans to increase neutralizing antibodies in nasal fluids that lasted at least 6 h.

14 July 2021 in medRxiv
Verified
Preprint
Open access
PDF file
VVVimvara Vacharathit
Vimvara Vacharathit
PAPakorn Aiewsakun
Pakorn Aiewsakun
SMSuwimon Manopwisedjaroen
Suwimon Manopwisedjaroen
CSChanya Srisaowakarn
Chanya Srisaowakarn
TLThanida Laopanupong
Thanida Laopanupong
Arunee ThitithanyanontArunee Thitithanyanont
Arunee Thitithanyanont
Recent surges in SARS-CoV-2 variants of concern (VOCs) call for the need to evaluate levels of vaccine-and infection-induced SARS-CoV-2 neutralizing antibodies (NAbs). CoronaVac (Sinovac Biotech, Beijing, China) is currently being used for mass vaccination in Thailand as well as other low-income countries. Three VOCs currently circulating within Thailand include the B.1.1.7 (Alpha), B.1.351 (Beta), and B.1.617.2 (Delta) strains. We assessed NAb potency against the prototypic strain containing the original spike sequence (WT) compared to that against the 3 VOCs using sera derived from a cohort of healthcare workers who received a full 2-dose regimen of CoronaVac. Sera from two other cohorts consisting of COVID-19 patients who had been hospitalized in 2020 and 2021 were evaluated for comparison. We found that, despite equally robust production of S1-RBD-binding IgG and 100% seropositivity, sera from both CoronaVac vaccinees and naturally infected individuals had significantly reduced neutralizing capacity against all 3 VOCs compared to WT. Strikingly, NAb titers against Alpha and Beta were comparable, but Delta appears to be significantly more refractory to NAbs in all groups. Our results may help inform on CoronaVac NAb-inducing capacity, which is a proxy for vaccine efficacy, in the context of the WT strain and 3 VOCs. Our results also have critical implications for public health decision-makers who may need to maintain efficient mitigation strategies amid a potentially high risk for infection with VOCs even in those who have been previously infected.

5 October 2022 in medRxiv
Verified
Preprint
Open access
PDF file
TIThanarath Imsuwansri
Thanarath Imsuwansri
TJThitinan Jongthitinon
Thitinan Jongthitinon
NPNiramon Pojdoung
Niramon Pojdoung
NMNuntana Meesiripan
Nuntana Meesiripan
SSSiriwan Sakarin
Siriwan Sakarin
TPTrairak Pisitkun
Trairak Pisitkun
Successful COVID-19 prevention requires additional measures beyond vaccination, social distancing, and masking. A nasal spray solution containing human IgG1 antibodies against SARS-CoV-2 (COVITRAP™) was developed to strengthen other COVID-19 preventive arsenals. Here, we evaluated its pseudovirus neutralization potencies, preclinical and clinical safety profiles, and intranasal SARS-CoV-2 inhibitory effects in healthy volunteers ( NCT05358873 ). COVITRAP™ exhibited broadly potent neutralizing activities against SARS-CoV-2 with PVNT 50 values ranging from 0.0035 to 3.1997 μg/ml for the following variants of concern (ranked from lowest to highest): Alpha, Beta, Gamma, Ancestral, Delta, Omicron BA.1, Omicron BA.2, Omicron BA.4/5, and Omicron BA.2.75. It demonstrated satisfactory preclinical safety profiles based on evaluations of in vitro cytotoxicity, skin sensitization, intracutaneous reactivity, and systemic toxicity. Its intranasal administration in rats did not yield any detected circulatory levels of the human IgG1 anti-SARS-CoV-2 antibodies at any time point during the 120 hours of follow-up. A double-blind, randomized, placebo-controlled trial (RCT) was conducted on 36 healthy volunteers who received either COVITRAP™ or a normal saline nasal spray at a 3:1 ratio. Safety of the thrice-daily intranasal administration for 7 days was assessed using nasal sinuscopy, adverse event recording, and self-reporting questionnaires. COVITRAP™ was well tolerated, with no significant adverse effects in healthy volunteers for the entire 14 days of the study. The intranasal SARS-CoV-2 inhibitory effects of COVITRAP™ were evaluated in nasal fluids taken from volunteers pre- and post-administration using a SARS-CoV-2 surrogate virus neutralization test. SARS-CoV-2 inhibitory effects in nasal fluids collected immediately or six hours after COVITRAP™ application were significantly increased from baseline for all three variants tested, including Ancestral, Delta, and Omicron BA.2. In conclusion, COVITRAP™ was safe for intranasal use in humans to provide SARS-CoV-2 inhibitory effects in nasal fluids that lasted at least six hours. Therefore, COVITRAP™ can be considered an integral instrument for COVID-19 prevention.

19 October 2016 in Cochrane Database of Systematic Reviews
Verified
Journal Article
Closed access
PDF file
TIThanarath Imsuwansri
Thanarath Imsuwansri
DHDerek James Hoare
Derek James Hoare
WPWanasri Phaisaltuntiwongs
Wanasri Phaisaltuntiwongs
ASAttasit Srisubat
Attasit Srisubat
KSKornkiat Snidvongs
Kornkiat Snidvongs

19 October 2020 in Cochrane Database of Systematic Reviews
Verified
Journal Article
Closed access
PDF file
TIThanarath Imsuwansri
Thanarath Imsuwansri
DHDerek J Hoare
Derek J Hoare
WPWanasri Phaisaltuntiwongs
Wanasri Phaisaltuntiwongs
ASAttasit Srisubat
Attasit Srisubat
KSKornkiat Snidvongs
Kornkiat Snidvongs